Sovaldi (sofosbuvir) / Gilead 
Welcome,         Profile    Billing    Logout  
 18 Diseases   22 Trials   22 Trials   2501 News 


«12...89101112131415161718...2122»
  • ||||||||||  Copegus (ribavirin) / Bausch Health, Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    Clinical, Journal:  Successful treatment with sofosbuvir and daclatasvir plus ribavirin in acute hepatitis C-infected patient with hepatic decompensation. (Pubmed Central) -  Jun 29, 2020   
    Serum hepatitis C virus RNA significantly declines after therapy and became undetectable at week 8 and it remained undetectable at 12 weeks after finishing therapy; sustained virological response was impressed. Our findings support that combination of sofosbuvir and daclatasvir plus ribavirin can be used for genotype 1b, AHC virus infection patients with overt hepatic decompensation.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Journal:  Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic. (Pubmed Central) -  Jun 28, 2020   
    The structural superposition of the hepatitis C virus polymerase bound to sofosbuvir, a nucleoside analog antiviral approved for hepatitis C virus infections, with the SARS-CoV polymerase shows that the residues that bind to the drug are present in the latter. Moreover, a multiple alignment of several SARS-CoV-2, SARS and MERS-related coronaviruses polymerases shows that these residues are conserved in all these viruses, opening the possibility to use sofosbuvir against these highly infectious pathogens.
  • ||||||||||  [VIRTUAL] Cost-based estimated prices for key HIV, HCV, and MDRTB medicines (Abstract Sessions On-Demand Channel) -  Jun 22, 2020 - Abstract #AIDS2020AIDS_1930;    
    Current prices for medicines are up to 1000 times more than cost-based estimated generic prices. Originator prices are often incongruous with country income level, with implications for access and scale-up of treatment programmes.
  • ||||||||||  Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead, elbasvir (MK-8742) / Merck (MSD)
    Journal, Combination therapy:  Optimization of a sensitive and robust strategy for micellar electrokinetic chromatographic analysis of sofosbuvir in combination with its co-formulated hepatitis C antiviral drugs. (Pubmed Central) -  Jun 19, 2020   
    Based on our previous work with "pseudostationary-ion exchanger sweeping", we use this strategy to develop a sensitive, reliable and robust method for the analysis of the newly-FDA approved hepatitis C antiviral drugs namely; sofosbuvir (SOV), daclatasvir (DAC), ledipasvir (LED) and velpatasvir (VEP) in their pure forms and co-formulated pharmaceutical dosage forms using micellar electrokinetic chromatography (MEKC) as a separation method...The selectivity of the developed method for determination of the studied compounds in their pharmaceutical dosage forms or in the presence of ribavirin (RIB) or elbasvir (ELB), which are other prescribed medications in the treatment regimen of patients with hepatitis C virus infection, is demonstrated. It is shown that with acidic sample matrix and basic BGE, an efficient and precise approach was designed in which analyte adsorption on the capillary wall was minimized while keeping repeatable peak height, peak area and migration time together with the highest possible enrichment efficiency.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Journal:  Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance. (Pubmed Central) -  Jun 6, 2020   
    NS5B resistance was rare, with a single case of sofosbuvir resistance...The impact of multiclass drug resistance on retreatment in people exposed to both NS3 and NS5A inhibitors needs to be assessed in real-world studies. Surveillance for increasing antiviral resistance during treatment scale-up is essential to maintain the efficacy of current DAA regimens.
  • ||||||||||  miravirsen (SPC3649) / BMS, Sovaldi (sofosbuvir) / Gilead
    Preclinical, Journal:  Replicons of a rodent hepatitis C model virus permit selection of highly permissive cells. (Pubmed Central) -  Jun 4, 2020   
    The microRNA-122 antagonist miravirsen inhibited RHV-rn1 replication, demonstrating the importance of this HCV host factor for RHV...HCV antivirals targeting NS5A, NS5B and microRNA-122 efficiently inhibited RHV replication. Hence, several important aspects of HCV replication are shared by the rodent virus system, reinforcing its utility as an HCV model.
  • ||||||||||  Copegus (ribavirin) / Bausch Health, Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    Clinical, PK/PD data, Journal:  The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin. (Pubmed Central) -  Jun 4, 2020   
    Hence, several important aspects of HCV replication are shared by the rodent virus system, reinforcing its utility as an HCV model. SNP genotyping for ABCB1 and ABCB11 genes can help in better personalized medicine for maximizing response for ribavirin as explored by the significant association between polymorphism in ABCB1 and ABCB11 genes and ribavirin pharmacokinetics and the significant association of ABCB11 1331 T > C SNP with clinical response.
  • ||||||||||  Daklinza (daclatasvir) / BMS
    [VIRTUAL] Improving access to care for serologically positive hepatitis C blood donors in private sector (Poster Area) -  May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-1743;    
    Integration of blood bank with clinical care services is possible through the use of minimal resources. There is a dire need for establishing a central database for sharing of information across various health care services including blood centers to improve access to care for hepatitis C.
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg., Sovaldi (sofosbuvir) / Gilead
    [VIRTUAL] Final challenges: real-world experience with sofosbuvir, velpatasvir and voxilaprevir in patients with advanced cirrhosis (Poster Area) -  May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-831;    
    This is the first Australian study to assess the real-world efficacy and safety of SOF/VEL/VOX amongst patients with advanced liver disease. SVR12 rates were good, but data suggests there remain a small number of very hard to cure patients, particularly those with GT3 and advanced disease, suggesting a need to explore strategies to optimise SVR in these groups.
  • ||||||||||  Daklinza (daclatasvir) / BMS
    [VIRTUAL] Dermatological manifestations in the era of new direct acting antivirals: a single-center experience (Poster Area) -  May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-813;    
    Our findings suggest patients treated with DAA may remain at risk for various dermatologic lesions development. Larger prospective studies of patients treated with DAA are needed to better describe the relationship between DAAs and incidence of various skin manifestations, as well as the prognosis of pre-existing lesions after DAA treatment.
  • ||||||||||  Copegus (ribavirin) / Bausch Health, sofosbuvir/velpatasvir / Generic mfg., Sovaldi (sofosbuvir) / Gilead
    [VIRTUAL] Innovative procedures for micro-elimination of HCV infection in a high-risk population of undocumented migrants and low-income refugees (Channel 5) -  May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-811;    
    HCV-RNA positive patients were treated with sofosbuvir plus velpatasvir + ribavirin for 12 weeks and followed up untreated for 12 weeks after treatment withdrawal Of the 3,401 migrants observed in the study period, 3,286 (96.6%) accepted to be screened. This innovative procedures for micro-elimination of HCV infection seems to be effective in undocumented migrants and lowincome refugees with rates of diagnosis, linkage to care and cure in line with the WHO goals
  • ||||||||||  pibrentasvir (ABT-530) / AbbVie, glecaprevir (ABT-493) / AbbVie
    [VIRTUAL] Second-generation DAAs for HCV: real-life efficacy in the resist-HCV cohort (Poster Area) -  May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-797;    
    Current DAA regimens, especially if pangenotypic, obtain response rates of at least 95% in a real-life situation. Adding ribavirin to SOF/VEL seems unnecessary in Gt3 patients, regardless of fibrosis.
  • ||||||||||  pibrentasvir (ABT-530) / AbbVie, velpatasvir (GS-5816) / Gilead
    [VIRTUAL] Resistance-associated variants conferring quite a high level of resistance to all approved NS5A inhibitors in genotype 2 hepatitis C virus (Poster Area) -  May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-794;    
    Genotype 2a-based HCV with NS5A-F28S/M31I showed significantly higher replication ability than the wild-type strain, and replication could not be suppressed, even with high concentrations of NS5A inhibitors, including pibrentasvir and velpatasvir (< 1000– 10000 fold-resistance compared with the wild-type strain). When performing retreatment for genotype 2a HCV-infected patients who fail to respond to DAAs, the optimized retreatment should be chosen according to the sensitivity of the emerging RAVs to anti-HCV drugs.
  • ||||||||||  ribavirin / Generic mfg., Sovaldi (sofosbuvir) / Gilead
    Clinical, Journal:  Characterization of Changes in Intrahepatic Immune Cell Populations During HCV Treatment with Sofosbuvir and Ribavirin. (Pubmed Central) -  May 29, 2020   
    Other cellular markers (CD56, CD20), as well as markers of apoptosis (TIA-1) and activated stellate cells, did not change significantly during treatment or differ by treatment outcome. The predominant intrahepatic cellular change during DAA treatment of chronic HCV infection is a reduction in CD8+ cellular density, but this did not correlate with treatment outcome.
  • ||||||||||  Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta
    Clinical, P2/3 data, Journal:  Glecaprevir/Pibrentasvir in Patients with Chronic HCV Genotype 3 Infection: An Integrated Phase 2/3 Analysis. (Pubmed Central) -  May 29, 2020   
    G/P was well-tolerated and efficacious for patients with chronic HCV GT3 infection, regardless of cirrhosis status or prior treatment experience. Eight- and 12-week durations were efficacious for treatment-naïve patients without cirrhosis and with compensated cirrhosis, respectively; 16-week G/P was efficacious in patients with prior treatment experience irrespective of cirrhosis status.
  • ||||||||||  Daklinza (daclatasvir) / BMS
    Clinical, Journal:  Expression of TRIM22 mRNA in Chronic Hepatitis C Patients Treated with Direct-Acting Antiviral Drugs. (Pubmed Central) -  May 27, 2020   
    Until 2014, pegylated interferon (PEG-IFN) plus ribavirin (RBV) has been the standard therapy for HCV, however, owing to its adverse side effects and very low sustained virologic response (SVR) rates therapeutics trend is shifted toward direct-acting antivirals...We have studied the expression levels of one of these antiviral effectors, TRIM22 in response to sofosbuvir (SOF) and daclatasvir (DAC) in combination with RBV, using quantitative PCR in the peripheral blood mononuclear cells (PBMCs) of HCV-infected patients...Genetic factors that determine the lower TRIM22 expression in these patients are needed to be explored that may also play a role in lower response to anti-HCV therapy. Endogenous IFN system and effects of antiviral proteins in response to DAA therapy is needed to be studied in order to better understand the host response towards these drugs to make them more effective.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Journal:  Sofosbuvir as a potential option for the treatment of COVID-19. (Pubmed Central) -  May 25, 2020   
    According the limited experimental evidences, it is hypothesized that sofosbuvir might be a potential option to improve care of patients with COVID-19 especially at the start of the disease and before invasion of the virus into the lung parenchymal cells. Efficacy and safety of sofosbuvir in treatment of COVID-19 may be considered in future clinical studies.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    Clinical, Journal:  No clear evidence for an effect of sofosbuvir against hepatitis E virus in organ-transplant-patients. (Pubmed Central) -  May 23, 2020   
    Treatment was stopped without confirming that HEV RNA became undetectable in the serum and the stools. It has been recently confirmed that the persistence of HEV shedding in the stools at the end of therapy is associated with a higher risk of relapse, and that prolonging the duration of ribavirin therapy allows eradicating HEV.